<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <atom:link rel="self" type="application/rss+xml" href="https://www.mynewsdesk.com/se/rss/current_news/118480"/>
    <title>Sobrera Pharma - Aktuellt</title>
    <link>https://www.mynewsdesk.com/se/sobrera-pharma</link>
    <description>Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg.</description>
    <image>
      <title>Sobrera Pharma - Aktuellt</title>
      <link>https://www.mynewsdesk.com/se/sobrera-pharma</link>
      <url>https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png</url>
      <width>128</width>
      <height>23</height>
    </image>
    <language>sv</language>
    <ttl>15</ttl>
<item>
  <title>Sobrera Pharma: Ny behandlingsstrategi minskar alkoholkonsumtionen</title>
  <pubDate>Thu, 26 Jun 2025 09:39:30 +0200</pubDate>
  <description>Två existerande läkemedel med kombinationseffekt på dopamin – vareniklin och bupropion - ger enligt en studie en statistisk minskning av alkoholkonsumtionen i patientgruppen. Resultaten har nyligen publicerats i tidskriften The Lancet Regional Health - Europe. </description>
  <guid>https://www.mynewsdesk.com/se/sobrera-pharma/pressreleases/sobrera-pharma-ny-behandlingsstrategi-minskar-alkoholkonsumtionen-3394074?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=current_news</guid>
  <link>https://www.mynewsdesk.com/se/sobrera-pharma/pressreleases/sobrera-pharma-ny-behandlingsstrategi-minskar-alkoholkonsumtionen-3394074?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=current_news</link>
  <dc:creator>Sobrera Pharma</dc:creator>
  <enclosure url="https://mnd-assets.mynewsdesk.com/image/upload/c_fill,dpr_auto,f_jpeg,g_auto,q_auto:good,w_1782/co55fn6txb42g6vz2oiybk" type="image/jpeg" length="0"/>
</item>
<item>
  <title>Sobrera Pharma: New treatment strategy reduces alcohol consumption</title>
  <pubDate>Thu, 26 Jun 2025 09:30:34 +0200</pubDate>
  <description>Two existing medications with complementary effect on dopamin - varenicline and bupropion - show in a study a statistically significant reduction in alcohol consumption in the patient population. The result has recently been published in The Lancet Regional Health – Europe.</description>
  <guid>https://www.mynewsdesk.com/se/sobrera-pharma/pressreleases/sobrera-pharma-new-treatment-strategy-reduces-alcohol-consumption-3394080?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=current_news</guid>
  <link>https://www.mynewsdesk.com/se/sobrera-pharma/pressreleases/sobrera-pharma-new-treatment-strategy-reduces-alcohol-consumption-3394080?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=current_news</link>
  <dc:creator>Sobrera Pharma</dc:creator>
  <enclosure url="https://mnd-assets.mynewsdesk.com/image/upload/c_fill,dpr_auto,f_jpeg,g_auto,q_auto:good,w_1782/fl0mxdcs0j0ribv8602mi1" type="image/jpeg" length="0"/>
</item>
<item>
  <title>Sobrera Pharma - Båda primära effektmåtten uppfyllda i fas 2-studie för behandling av alkoholberoende</title>
  <pubDate>Thu, 27 Apr 2023 11:17:27 +0200</pubDate>
  <description>Sobrera Pharma AB, ett svenskt läkemedelsföretag som utvecklar medicinsk behandling för alkoholberoende, har idag offentliggjort positiva resultat från en fas 2-studie ledd av Gruppen för Beroendemedicin vid Göteborgs Universitet. Studien visar en statistiskt signifikant minskning av alkoholkonsumtionen i den läkemedelsbehandladegruppen jämfört med placebo.</description>
  <guid>https://www.mynewsdesk.com/se/sobrera-pharma/pressreleases/sobrera-pharma-baada-primaera-effektmaatten-uppfyllda-i-fas-2-studie-foer-behandling-av-alkoholberoende-3249112?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=current_news</guid>
  <link>https://www.mynewsdesk.com/se/sobrera-pharma/pressreleases/sobrera-pharma-baada-primaera-effektmaatten-uppfyllda-i-fas-2-studie-foer-behandling-av-alkoholberoende-3249112?utm_source=rss&amp;utm_medium=rss&amp;utm_campaign=Subscription&amp;utm_content=current_news</link>
  <dc:creator>Sobrera Pharma</dc:creator>
  <enclosure url="https://mnd-assets.mynewsdesk.com/image/upload/c_fill,dpr_auto,f_jpeg,g_auto,q_auto:good,w_1782/nw4fkchs73v4vcmtrruf" type="image/jpeg" length="0"/>
</item>
  </channel>
</rss>
